Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Conglin Zuo"'
Autor:
Wei Wu, Juan Zhou, Chuandong Wu, Qian Zhou, Xiaoyu Li, Yanlin Zhang, Conglin Zuo, Jun Yin, Ling Hou, Shuyang Wang, Hongyang Gao, Tianhong Luo, Lei Jin, Enhong Zhong, Yingwu Wang, Xiaoping Luo
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Jintrolong® is a long-acting PEGylated recombinant human growth hormone (PEG-rhGH) developed for weekly injection in patients with pediatric growth hormone deficiency (PGHD). Although PEG modification of therapeutic proteins is generally considered
Externí odkaz:
https://doaj.org/article/97e8687a3d664d16bf328b4525f3edab
Autor:
Wei, Wu, Juan, Zhou, Chuandong, Wu, Qian, Zhou, Xiaoyu, Li, Yanlin, Zhang, Conglin, Zuo, Jun, Yin, Ling, Hou, Shuyang, Wang, Hongyang, Gao, Tianhong, Luo, Lei, Jin, Enhong, Zhong, Yingwu, Wang, Xiaoping, Luo
Publikováno v:
Frontiers in endocrinology. 13
Jintrolong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eddbac64232df64126f505e1b5fc521a
https://pubmed.ncbi.nlm.nih.gov/35909512
https://pubmed.ncbi.nlm.nih.gov/35909512
Autor:
Conglin Zuo, Lei Zhang, Yunxia Sun, Zhongchao Han, Jinling Ma, Zhibo Han, Youwei Wang, Hongzhen Li, Wei Gong, Yanan He, Bin Wang, Geng Jie
Publikováno v:
Stem Cells and Development. 21:1401-1408
Therapies based on stem cells have shown very attractive potential in many clinical studies. However, the data about the safety of stem cells application remains insufficient. The present study was designed to evaluate the overall toxicology of human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c6a7b23325d740d29c794e9fb7f31aa
https://doi.org/10.1089/scd.2011.0441
https://doi.org/10.1089/scd.2011.0441
Autor:
Conglin, Zuo, Mingbo, Xu, Yongbo, Wang, Hui, Yi, Yuxia, Feng, Tao, Li, Xiuzhen, Liu, Xiangdong, Huang
Publikováno v:
Zhongguo shi yan xue ye xue za zhi. 8(1)
Hematological effects of rhIL-11 on normal and myelosuppressed male BALB/c mice were observed. Mice were subcutaneously injected with rhIL-11 for 7 consecutive days, at the dose of 200 or 400 micro g/kg per day, peripheral blood platelet counts were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85eb22a218cde16a2f833e09637a1940
https://pubmed.ncbi.nlm.nih.gov/12578714
https://pubmed.ncbi.nlm.nih.gov/12578714
Autor:
Conglin, Zuo, Mingbo, Xu, Yongbo, Wang, Hui, Yi, Yuxia, Feng, Tao, Li, Xiuzhen, Liu, Xiangdong, Huang
Publikováno v:
Zhongguo shi yan xue ye xue za zhi. 8(1)
A model of myelosuppression with thrombocytopenia was produced in monkey by i.v. administration of carboplatin to the evaluate effects of rhIL-11 treatment in monkeys. Following myelosuppression, rhIL-11 was subcutaneously injected for 19 consecutive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e64f8cb7b28f5f76a2180546cb80578f
https://pubmed.ncbi.nlm.nih.gov/12578715
https://pubmed.ncbi.nlm.nih.gov/12578715